NGF and Miyoshi myopathy: Thus, results in a large cohort of 137 real-world MM patients treated outside of clinical trials demonstrated CTPC by NGF in 26% of treated MM cases, including 17% of cases who had achieved complete response/stringent complete response [35], a significantly greater percentage than previously shown by conventional multiparameter flow cytometry approaches [34,116,125,126].